VLT-201
Moderate-to-severe ulcerative colitis
Oral small moleculePhase 2
A gut-restricted modulator of pathogenic Th17 signalling, designed to reduce mucosal inflammation with limited systemic exposure.
DiscoveryPreclinicalPhase 1Phase 2Phase 3
Pipeline
Pipeline
Our development portfolio spans discovery through Phase 2, concentrated in autoimmune, inflammatory and fibrotic disease.
VLT-118
Systemic lupus erythematosus
Monoclonal antibodyPhase 1
A first-in-class antibody targeting an interferon-driven B cell axis identified in patient tissue profiling.
DiscoveryPreclinicalPhase 1Phase 2Phase 3
VLT-340
Idiopathic pulmonary fibrosis
Oral small moleculePhase 1
A selective fibroblast activation inhibitor intended to slow progressive lung remodelling.
DiscoveryPreclinicalPhase 1Phase 2Phase 3
VLT-405
Cutaneous lupus erythematosus
Topical small moleculePreclinical
A locally applied candidate under IND-enabling study for chronic cutaneous disease.
DiscoveryPreclinicalPhase 1Phase 2Phase 3
Discovery portfolio
Autoimmune and inflammatory disease
Multiple modalitiesDiscovery
Three undisclosed programs advancing through target validation within our human-first discovery engine.
DiscoveryPreclinicalPhase 1Phase 2Phase 3
New program
Indication
Small moleculeDiscovery
DiscoveryPreclinicalPhase 1Phase 2Phase 3
Development stages shown reflect the most advanced indication for each program and are updated following regulatory milestones.